143 related articles for article (PubMed ID: 7930754)
1. Economic analysis of investment priorities for measles control.
Shepard DS
J Infect Dis; 1994 Nov; 170 Suppl 1():S56-62. PubMed ID: 7930754
[TBL] [Abstract][Full Text] [Related]
2. Measles: not just another viral exanthem.
Duke T; Mgone CS
Lancet; 2003 Mar; 361(9359):763-73. PubMed ID: 12620751
[TBL] [Abstract][Full Text] [Related]
3. Assessing the cost-effectiveness of different measles vaccination strategies for children in the Democratic Republic of Congo.
Doshi RH; Eckhoff P; Cheng A; Hoff NA; Mukadi P; Shidi C; Gerber S; Wemakoy EO; Muyembe-Tafum JJ; Kominski GF; Rimoin AW
Vaccine; 2017 Oct; 35(45):6187-6194. PubMed ID: 28966000
[TBL] [Abstract][Full Text] [Related]
4. Economic analysis of measles elimination program in the Republic of Korea, 2001: a cost benefit analysis study.
Bae GR; Choe YJ; Go UY; Kim YI; Lee JK
Vaccine; 2013 May; 31(24):2661-6. PubMed ID: 23602654
[TBL] [Abstract][Full Text] [Related]
5. Modeling the Transmission of Measles and Rubella to Support Global Management Policy Analyses and Eradication Investment Cases.
Thompson KM; Badizadegan ND
Risk Anal; 2017 Jun; 37(6):1109-1131. PubMed ID: 28561947
[TBL] [Abstract][Full Text] [Related]
6. Global eradication of measles: an epidemiologic and economic evaluation.
Levin A; Burgess C; Garrison LP; Bauch C; Babigumira J; Simons E; Dabbagh A
J Infect Dis; 2011 Jul; 204 Suppl 1():S98-106. PubMed ID: 21666220
[TBL] [Abstract][Full Text] [Related]
7. Economic value of vaccinating geographically hard-to-reach populations with measles vaccine: A modeling application in Kenya.
Lee BY; Brown ST; Haidari LA; Clark S; Abimbola T; Pallas SE; Wallace AS; Mitgang EA; Leonard J; Bartsch SM; Yemeke TT; Zenkov E; Ozawa S
Vaccine; 2019 Apr; 37(17):2377-2386. PubMed ID: 30922700
[TBL] [Abstract][Full Text] [Related]
8. The cost saving opportunity of introducing a card review into measles-containing vaccination campaigns.
Hagedorn BL; Dabbagh A; McCarthy KA
Vaccine; 2019 Sep; 37(41):6093-6101. PubMed ID: 31471145
[TBL] [Abstract][Full Text] [Related]
9. The economic disease burden of measles in Japan and a benefit cost analysis of vaccination, a retrospective study.
Takahashi K; Ohkusa Y; Kim JY
BMC Health Serv Res; 2011 Oct; 11():254. PubMed ID: 21978107
[TBL] [Abstract][Full Text] [Related]
10. Strategic planning for measles control: using data to inform optimal vaccination strategies.
Simons E; Mort M; Dabbagh A; Strebel P; Wolfson L
J Infect Dis; 2011 Jul; 204 Suppl 1():S28-34. PubMed ID: 21666174
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of measles elimination in Latin America and the Caribbean: a prospective analysis.
Acharya A; Diaz-Ortega JL; Tambini G; de Quadros C; Arita I
Vaccine; 2002 Sep; 20(27-28):3332-41. PubMed ID: 12213403
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of supplementary immunization for measles in India.
Dabral M
Indian Pediatr; 2009 Nov; 46(11):957-62. PubMed ID: 19578225
[TBL] [Abstract][Full Text] [Related]
13. Economic analysis of the 1996-1997 mass measles immunization campaigns in South Africa.
Uzicanin A; Zhou F; Eggers R; Webb E; Strebel P
Vaccine; 2004 Sep; 22(25-26):3419-26. PubMed ID: 15308367
[TBL] [Abstract][Full Text] [Related]
14. Modeling the economic impact of different vial-opening thresholds for measles-containing vaccines.
Wedlock PT; Mitgang EA; Oron AP; Hagedorn BL; Leonard J; Brown ST; Bakal J; Siegmund SS; Lee BY
Vaccine; 2019 Apr; 37(17):2356-2368. PubMed ID: 30914223
[TBL] [Abstract][Full Text] [Related]
15. Using cost-effectiveness analysis to support research and development portfolio prioritization for product innovations in measles vaccination.
Garrison LP; Bauch CT; Bresnahan BW; Hazlet TK; Kadiyala S; Veenstra DL
J Infect Dis; 2011 Jul; 204 Suppl 1():S124-32. PubMed ID: 21666153
[TBL] [Abstract][Full Text] [Related]
16. Determining measles-containing vaccine demand and supply: an imperative to support measles mortality reduction efforts.
Costa A; Henao-Restrepo AM; Marie Hall S; Jarrett S; Hoekstra EJ
J Infect Dis; 2003 May; 187 Suppl 1():S22-8. PubMed ID: 12721888
[TBL] [Abstract][Full Text] [Related]
17. [Evaluation of vaccination policies. The case of measles].
Lafarge H; Levy E; Rey M
Rev Epidemiol Sante Publique; 1985; 33(3):182-93. PubMed ID: 4081224
[TBL] [Abstract][Full Text] [Related]
18. Two-dose measles vaccination schedules.
Rosenthal SR; Clements CJ
Bull World Health Organ; 1993; 71(3-4):421-8. PubMed ID: 8324862
[TBL] [Abstract][Full Text] [Related]
19. Impact of mass measles campaigns among children less than 5 years old in Uganda.
Nanyunja M; Lewis RF; Makumbi I; Seruyange R; Kabwongera E; Mugyenyi P; Talisuna A
J Infect Dis; 2003 May; 187 Suppl 1():S63-8. PubMed ID: 12721893
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of providing measles vaccination to all children in Guinea-Bissau.
Byberg S; Fisker AB; Thysen SM; Rodrigues A; Enemark U; Aaby P; Benn CS; Griffiths UK
Glob Health Action; 2017; 10(1):1329968. PubMed ID: 28580855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
